SELLAS Life Sciences Group, Inc.

NASDAQ:SLS

Biotechnology

Healthcare
$17.95 +4.02%

+$0.31 today

Market cap
$3.66B
Beta
2.53
P/E (TTM)
-47.3
EPS (TTM)
-$0.17
52W Low $1.39High $9.51

Volume 35.53M

Average 7.79M

Cash Flow

Check whether earnings turn into cash.

Operating Cash Flow

-$28.39M

FY 2025 · Annual

Investing Cash Flow

$0.00

FY 2025 · Annual

Financing Cash Flow

$86.30M

FY 2025 · Annual

+84.6% YoY

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(20.7M)(41.3M)(37.34M)(30.88M)(26.86M)
Depreciation & Amortization1.27M457K37.87M31.51M0
Deferred Income Tax(239K)(457K)000
Stock-Based Compensation1.01M1.73M1.39M1.56M1.96M
Change in Working Capital(7.62M)5.64M3.35M(6.65M)(4.08M)
Accounts Receivables00000
Inventory00000
Accounts Payables(2.51M)1.21M2.3M(2.14M)(535K)
Other Working Capital(5.1M)4.43M1.04M(4.51M)(3.54M)
Other Non-Cash Items248K10.13M(36.67M)(30.95M)597K
Operating Cash Flow(26.02M)(23.81M)(31.41M)(35.4M)(28.39M)
Capital Expenditures0(4.5M)(5.5M)00
Acquisitions (Net)00000
Purchases of Investments00000
Sales of Investments00000
Other Investing Activities00000
Investing Cash Flow0(4.5M)(5.5M)00
Debt Repayment00000
Common Stock Issued9.01M23.99M22.23M46.16M86.82M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities3.07M85K90K594K(527K)
Financing Cash Flow12.07M24.08M22.32M46.76M86.3M
Effect of Forex Changes00000
Net Change in Cash(13.95M)(4.23M)(14.6M)11.36M57.91M
Free Cash Flow(26.02M)(28.31M)(36.91M)(35.4M)(28.39M)

Free Cash Flow

Net Income to FCF bridge

FY2025

= Net Income-$26.9M
+ D&A$0
+ Stock-Based Comp$2.0M
+ Deferred Tax$0
- Working Capital-$4.1M
+ Other Non-Cash$597.0K
= Operating Cash Flow-$28.4M
- Capex$0
= Free Cash Flow-$28.4M

Analysis

FY2025 free cash flow is -$28.4M. FCF conversion is 105.7% of net income. Operating cash flow was -$28.4M, with capex of $0. The largest bridge item is Working Capital at -$4.1M.

Recent Filings

Recent regulatory filings

FilingDescriptionDate
10-QQuarterly reportNov 12, 2026
8-KCurrent reportNov 12, 2026
SC 13GSC 13G filingNov 10, 2026
SC 13G/ASC 13G/A filingOct 27, 2026
10-QQuarterly reportAug 11, 2026

Does SLS generate free cash flow?

SELLAS Life Sciences Group, Inc. (SLS) generated -$28.39M of free cash flow in fiscal 2025.

How much operating cash flow does SLS produce?

Operating cash flow was -$28.39M, before capital expenditures of $0.00.